Clinical Trial Update: Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, pharmacokinetics and preliminary efficacy of CFZ533 in lupus nephritis has completed, with results posted on 2024-07-18. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• CFZ533

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lupus Nephritis | Phase 2 | Status: COMPLETED | Results posted: 2024-07-18